Omnicell (OMCL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.94
- Estimate
- $0.47
- Surprise
- +101.1%
- Score at report (before → after)
- 5.6 → 6.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Omnicell (OMCL) beat the $0.47 estimate with adjusted EPS of $0.94 — a large 101.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.6/10) to Hold at 6.1/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates OMCL Sell at 5.4/10.
3 of the last 4 quarters beat the estimate; this quarter's +101.1% surprise compares with a +47.1% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
- Below 200-MA, MA slope -2.4%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $35.43
- Price target
- $50.34
- Stop
- $33.13
- Upside to target
- +42.1%
- Reward-to-risk
- 4.3:1
The stock trades at 43.4× trailing but 17.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
OMCL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $1.66B
- P/E (fwd)
- 17.4
- P/E (ttm)
- 43.4
- 52-week range
- $29.06–$55.00
- Off 52-week high
- 35.6%
- RSI (14)
- 64
- Volume vs avg
- 0.49×
- Score today
- 5.4/10